针对脏的向治疗策略
Fei Yuan1,2, Lilach O Lerman1,3
1Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
Expert opinion on therapeutic targets
|November 4, 2024
概括
针对脏的新型疗法显示出治疗脏疾病的前景,提供了新的希望. 然而,临床转化中的挑战需要进一步的研究和开发,以有效治疗脏疾病.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 生物医学工程 生物医学工程
- 药理学 药理学是指药理学的学科.
背景情况:
- 脏疾病是一个重大的全球健康挑战,有效的治疗方法有限.
- 开发新的治疗策略对于延迟或逆转病进展至关重要.
- 向疗法为改善脏疾病治疗结果提供了一个有希望的方法.
研究的目的:
- 审查脏向治疗的最新进展.
- 探索包括基因,,蛋白质,基于细胞和纳米粒子传递系统在内的各种模式.
- 讨论这些针对脏疾病的向治疗的临床应用,未来前景和挑战.
主要方法:
- 对脏疾病的向治疗方法的综合文献综述.
- 对不同输送系统和治疗剂的分析.
- 评估当前的临床应用和未来的潜力.
主要成果:
- 针对性疗法的进展表明,有潜力提高脏疾病的治疗结果.
- 目前正在研究各种方法,如基因疗法,,蛋白质,基于细胞的疗法和纳米粒子.
- 为了提高疗效,也在探索局部化输送路径.
结论:
- 向治疗对改善脏疾病的管理具有重大前景.
- 临床翻译受到复杂的结构和缺乏特定生物标志物的阻碍.
- 克服临床前研究和临床应用中的挑战对于实现脏向治疗的全部潜力至关重要.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
391
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
391
Antihypertensive Drugs: Direct Renin Inhibitors
498
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
498
Drug Elimination by Renal Route: Tubular Secretion
2.2K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
2.2K
Targets for Drug Action: Overview
6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K
Renal Drug Excretion: Tubular Secretion
144
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
144


